On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Read More: ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated price ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with groundbreaking discoveries, cutting-edge research, and influential biotech ...

Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that ...